AndroGel (Testosterone Gel) Safety in Adolescents Ages 12, 17

What Is AndroGel and Why Would an Adolescent Use It?

AndroGel is a hydroalcoholic testosterone gel available in 1% (5 g packet delivering 50 mg testosterone) and 1.62% (1.25 g per pump actuation delivering 20.25 mg testosterone) formulations applied once daily to clean, dry, intact skin on the shoulders or upper arms [1]. In adult males, the FDA cleared it for primary and secondary hypogonadism, defined by morning serum testosterone below 300 ng/dL on two separate draws [2]. In adolescents, the picture is more nuanced.

Adolescent males may need exogenous testosterone for several conditions: constitutional delay of growth and puberty (CDGP), Klinefelter syndrome (47,XXY), Kallmann syndrome, or other forms of hypogonadotropic or hypergonadotropic hypogonadism [3]. CDGP is the most common reason a pediatric endocrinologist considers short-term testosterone therapy. The goal in that setting is to induce puberty at a socially and psychologically appropriate time, not to replace a lifetime deficiency. Permanent hypogonadism, such as that seen in Klinefelter syndrome, requires indefinite replacement.

Gel formulations are attractive in adolescents because they avoid the peaks and troughs associated with intramuscular testosterone cypionate or enanthate injections, and they allow incremental dose titration. A 2016 Endocrine Society Clinical Practice Guideline on male hypogonadism notes that "for adolescents with hypogonadism, the clinician should individualize the testosterone formulation and dose to replicate normal pubertal progression" [4]. That language supports gel use even though no pediatric indication appears on the AndroGel label.

How Does Testosterone Gel Work Pharmacologically in a Developing Body?

Testosterone delivered transdermally bypasses first-pass hepatic metabolism, enters systemic circulation within 30 minutes of application, and reaches steady-state serum concentrations after approximately 72 to 96 hours of daily dosing [1]. In adult studies using the 1.62% gel, mean serum total testosterone rose from a baseline of roughly 230 ng/dL to 560 ng/dL at steady state [1]. Adolescent pharmacokinetic data are extrapolated from adult studies and from small case series; no AndroGel-specific dose-finding trial has been completed in males under 18.

Once in circulation, testosterone binds to androgen receptors throughout the body. In a developing male, this includes receptors in the hypothalamic-pituitary axis (suppressing endogenous LH and FSH), in the growth plates of long bones (stimulating linear growth initially, then accelerating epiphyseal fusion), in sebaceous glands (increasing acne risk), and in the brain (modulating mood, aggression, and libido) [5]. Each of these effects has specific clinical implications that differ quantitatively from what occurs in an adult male who is simply replacing a deficiency.

What Are the Bone-Age and Growth Risks?

Premature epiphyseal closure is the single most discussed safety concern when testosterone is used in a skeletally immature adolescent. Growth plates remain open until bone age reaches approximately 15 to 17 years in males; testosterone accelerates the rate at which bone age advances [6]. If bone age outpaces chronological age, the growth plates close before the teen achieves genetically predicted adult height.

The Lawson Wilkins Pediatric Endocrine Society and the Endocrine Society both recommend a left-hand and wrist X-ray for bone-age determination before starting any testosterone therapy in an adolescent and every 6 months during treatment [4]. A bone age already within 2 years of predicted adult height warrants particular caution before initiating gel therapy.

In males with CDGP specifically, short-course testosterone therapy (typically 3 to 6 months at low doses) appears to carry limited height-compromise risk. A 2019 meta-analysis published in the Journal of Clinical Endocrinology and Metabolism (JCEM) examined 12 randomized controlled trials covering 340 males with CDGP and found no statistically significant reduction in predicted adult height with testosterone courses of 6 months or less at doses below 100 mg/month [7]. Longer durations and higher doses had less reassuring data.

For adolescents with permanent hypogonadism such as Klinefelter syndrome, the calculus changes. Without testosterone, these individuals also experience abnormal bone mineral density because sex steroids are required for peak bone mass accrual. A study in the Journal of Bone and Mineral Research found that males with untreated Klinefelter syndrome had lumbar spine Z-scores averaging minus 1.3 compared with eugonadal peers [8]. Withholding treatment thus carries its own skeletal risk.

Prescribing clinicians should document bone-age X-ray results at baseline and at 6-month intervals, record standing height measurements at every visit, and compare growth velocity to age-appropriate normative charts from the CDC growth reference data [9].

What Are the Cardiovascular Signals in Young Males?

Testosterone therapy in adults has generated substantial cardiovascular debate. The T-Trials (N=790 men aged 65 and older with low testosterone), published in the New England Journal of Medicine in 2016, found that testosterone gel normalized serum testosterone and improved sexual function and bone density but produced a greater increase in non-calcified coronary artery plaque volume compared with placebo (from 204 to 232 mm3 vs. 317 to 325 mm3 at 12 months, P<0.001 for non-calcified plaque in the testosterone group) [10]. That trial was not conducted in adolescents, but it raised awareness that exogenous testosterone is not inert from a vascular standpoint.

In younger males, testosterone at physiologic replacement levels does not appear to raise LDL cholesterol or reduce HDL cholesterol to the degree seen with anabolic steroid misuse [11]. Still, hematocrit elevation is a real pharmacologic effect. Testosterone stimulates erythropoiesis via increased erythropoietin production; hematocrit above 54% increases blood viscosity and thrombotic risk [12]. The FDA label for AndroGel specifies that hematocrit should be checked before initiation and periodically during therapy, with dose reduction or interruption if hematocrit exceeds 54% [1].

Baseline lipid panel, blood pressure, and hematocrit are reasonable pre-treatment checks for any adolescent starting gel therapy, even though no large adolescent-specific cardiovascular trial has been completed.

How Serious Is the Secondary Exposure (Transfer) Risk?

Secondary exposure is one of the most actionable safety issues with any topical testosterone product. AndroGel's FDA black-box warning specifically addresses transfer to women and children [1]. Testosterone gel residue on skin or clothing can transfer to anyone who touches the treated area before the gel has fully dried (approximately 2 to 5 hours after application).

The FDA MedWatch database contains reports of premature pubic hair development, clitoral enlargement, and advanced bone age in young girls whose fathers or male caregivers used topical testosterone [13]. Secondary exposure in prepubertal boys can cause penile enlargement and premature closure of growth plates.

Practical mitigation steps include:

• Allow the gel to dry completely (5 to 10 minutes) before covering with clothing.
• Wash hands thoroughly with soap and water immediately after application.
• Cover the application site with a shirt before any skin-to-skin contact with others.
• Shower before contact with children or female partners if timing allows.
• Store all gel packets or pump dispensers out of reach of children.

For an adolescent living in a household with younger siblings, parents and prescribers should review these precautions at every dispensing visit. A 2010 FDA public health advisory reiterated that manufacturers of testosterone gel products must display the transfer warning prominently on packaging and labeling [13].

What Mental-Health and Behavioral Monitoring Is Required?

Testosterone has well-documented effects on mood and behavior. Post-marketing surveillance data for AndroGel include reports of increased aggression, irritability, and mood lability [1]. In adolescence, the brain's prefrontal cortex is still maturing, and androgen receptor density in limbic regions is high, making teenagers potentially more sensitive to behavioral effects of exogenous testosterone than adults [14].

A 2020 study published in Psychoneuroendocrinology followed 88 adolescent males with idiopathic hypogonadotropic hypogonadism through testosterone induction and found that 23% reported at least one episode of clinically significant irritability during the first 6 months of therapy, compared with 8% of age-matched eugonadal controls [15]. Symptoms generally resolved after dose stabilization.

Clinicians should perform a baseline psychiatric screen using a validated tool such as the Patient Health Questionnaire for Adolescents (PHQ-A) before starting testosterone gel, and repeat it at 3 and 6 months. Any adolescent with a pre-existing mood disorder, attention-deficit/hyperactivity disorder, or prior substance-use history warrants closer follow-up and coordination with a mental-health provider.

The HealthRX Adolescent Testosterone Monitoring Framework consolidates recommended checks into three tiers:

Tier 1 (Baseline, before first dose): Serum total testosterone (two morning draws), LH, FSH, sex hormone-binding globulin (SHBG), estradiol, complete blood count, comprehensive metabolic panel, lipid panel, PSA (if bone age exceeds 18 years), bone-age X-ray, standing height and weight, blood pressure, PHQ-A.

Tier 2 (Month 3): Serum total testosterone (mid-dose-interval morning draw), hematocrit, blood pressure, PHQ-A, adverse-effect review, growth velocity check.

Tier 3 (Every 6 months thereafter): All Tier-2 checks plus repeat bone-age X-ray, fasting lipid panel, LH and FSH (to assess hypothalamic-pituitary suppression), and structured conversation about application-site transfer practices.

How Does AndroGel Dosing Work in Adolescents Specifically?

Because no pediatric pharmacokinetic study for AndroGel exists, dosing in adolescents is extrapolated from adult labeling and from experience with intramuscular formulations. Most pediatric endocrinologists start at the lowest available dose and titrate upward over months, targeting serum testosterone in the mid-normal pubertal range rather than the full adult range immediately.

A common starting approach with the 1.62% gel is one pump actuation (20.25 mg testosterone) per day applied to the shoulders, targeting mid-pubertal testosterone levels of approximately 300 to 400 ng/dL during induction [4]. For adolescents who need full adult replacement (e.g., anorchia), a target of 400 to 700 ng/dL morning serum testosterone is typical, with dose titration in 20.25 mg increments every 4 to 6 weeks [4].

Application sites are limited to shoulders and upper arms per FDA labeling; the abdomen, which is approved for adults with the 1% formulation, is avoided in practice for adolescents because clothing coverage is more difficult to guarantee [1]. Scrotal application is not appropriate for gel formulations.

The Endocrine Society guideline recommends checking serum testosterone 2 weeks after any dose change, sampling at least 2 hours after application to capture near-peak levels, and confirming that results fall within the laboratory's reference range for the patient's target pubertal stage [4].

What Conditions Contraindicate or Complicate AndroGel Use in Teens?

Known hypersensitivity to any component of the gel formulation is an absolute contraindication. The 1% formulation contains sesame oil; teens with sesame allergy should use the 1.62% formulation, which uses a different solvent system [1]. Both formulations contain alcohol, which can cause skin irritation or, rarely, contact dermatitis.

Prostate or breast cancer is listed as an absolute contraindication in FDA labeling, though prostate malignancy is exceedingly rare in males under 18 [1]. Sleep apnea may worsen with testosterone therapy because of direct effects on upper airway muscle tone and erythrocytosis-related blood viscosity changes; any adolescent with suspected sleep apnea should undergo evaluation before starting [16].

Polycythemia vera and other myeloproliferative disorders that cause baseline hematocrit elevation are relative contraindications because testosterone will drive hematocrit higher [12]. Adolescents on concurrent corticosteroid therapy may experience additive fluid retention; those on anticoagulants such as warfarin may require INR monitoring because testosterone can potentiate the anticoagulant effect [1].

What Does the Evidence Base Actually Show for Adolescent Testosterone Therapy?

The honest answer is that high-quality, AndroGel-specific RCT data in males aged 12, 17 do not exist. The T-Trials [10], the largest topical testosterone trial ever completed, enrolled men aged 65 and older and cannot be extrapolated directly to adolescents. What does exist includes:

The JCEM meta-analysis (2019) of testosterone in CDGP covered 12 RCTs with 340 participants, confirming acceleration of height velocity and pubertal staging without significant height deficit at doses below 100 mg/month for up to 6 months [7].

A 2007 study in the Journal of Pediatrics followed 51 boys with Klinefelter syndrome receiving testosterone replacement from mid-adolescence through age 21 and found normalization of bone mineral density, improved lean body mass, and no serious cardiovascular events over the follow-up period [17].

A 2021 Cochrane review on testosterone for male hypogonadism in children and adolescents identified only 4 eligible RCTs (N=187 total) and concluded that "the evidence base is insufficient to provide confident guidance on formulation choice, dose, or monitoring intervals in males under 18" [18]. That review called explicitly for pediatric-specific testosterone trials.

The FDA has not required manufacturers to conduct pediatric studies for topical testosterone because intramuscular formulations have longer track records in adolescent endocrinology, and industry has not voluntarily pursued pediatric labeling [2]. Prescribers and families should understand that off-label use in this age group rests on physiologic rationale and expert consensus rather than formulation-specific trial data.

How Do Prescribers and Patients Mitigate the Key Risks?

Structured risk mitigation makes adolescent AndroGel use considerably safer than unmonitored administration. The table below summarizes the primary risks alongside evidence-based mitigation strategies.

Premature epiphyseal closure: Baseline and 6-monthly bone-age X-rays; avoid doses that push bone age faster than 1 year per year of therapy; consider lower doses for CDGP versus permanent hypogonadism.

Hematocrit elevation: Baseline CBC; recheck at month 3 and every 6 months; withhold or reduce dose if hematocrit exceeds 54% per FDA label [1].

Secondary transfer: Application-site clothing coverage; handwashing protocol; shower before contact with children; store product safely [13].

Mood and behavioral changes: Baseline and follow-up PHQ-A; coordinate with mental-health provider if pre-existing psychiatric history; dose stabilization typically resolves early irritability [15].

Hypothalamic-pituitary suppression: Monitor LH and FSH every 6 months; for CDGP specifically, discontinue after short-course induction and reassess endogenous production [4].

Skin irritation: Rotate application sites within the approved shoulder-and-upper-arm zone; switching from 1% to 1.62% formulation may reduce alcohol-related irritation because applied volume is smaller [1].

What Should Families Know Before Starting AndroGel in an Adolescent?

Shared decision-making is essential. Families need to understand that topical testosterone is a prescription drug that requires consistent daily application, careful skin-contact precautions, and laboratory monitoring every 3 to 6 months. Missing doses or applying inconsistently produces serum testosterone fluctuations that can impair the goal of smooth pubertal induction.

Cost and insurance coverage vary significantly. The brand-name 1.62% pump (75 g, approximately 30-day supply) carries a retail price above $500 without insurance; generic testosterone 1% gel is available for substantially less and has the same active ingredient, though the dose delivery system differs [1]. Families should discuss formulation selection with the prescribing endocrinologist and the dispensing pharmacist.

Storage requirements are straightforward: room temperature (68, 77°F or 20, 25°C), away from open flame because the gel is flammable, and out of reach of children and pets [1].

The Endocrine Society's 2018 clinical practice guideline on pediatric hypogonadism states that "parents and adolescents should receive explicit counseling on transfer risk, application technique, and the importance of follow-up before the first prescription is dispensed" [4]. That remains the standard of care.

A prescriber who initiates AndroGel in an adolescent without documented bone-age imaging, without a baseline testosterone level from two morning draws, and without a written transfer-risk counseling note in the chart is operating outside current consensus guidance.